Crescendo Biologics

Crescendo Biologics is a private, clinical-stage biotech leveraging its proprietary Humabody® VH platform to develop next-generation, multi-specific immune cell engagers for cancer. Its lead asset, CB307, is a bispecific in Phase 1b for metastatic castration-resistant prostate cancer (mCRPC), with a second program, CB001/ZL-1102 for psoriasis, in Phase 2 via partner Zai Lab. The company is backed by blue-chip investors and has significant discovery and development collaborations with Takeda, BioNTech, and Zai Lab, validating its platform and providing non-dilutive funding.

Humabody® VH platform: proprietary technology for generating small, fully human, single-domain antibody fragments (VH domains) that require no humanization. These stable domains can be engineered into multi-specific formats (MultiBody®s) with advantages in tissue penetration, epitope access, and tunable pharmacokinetics.

Crescendo competes in the crowded bispecific T cell engager and immune agonist space against large pharma and biotech firms. Its key differentiation is the small size and fully human nature of its Humabody building blocks, which may offer advantages in solid tumor penetration and reduced immunogenicity compared to some antibody-based formats.